IDEXX Laboratories, Inc. $IDXX Shares Sold by Barclays PLC

Key Points

• Barclays reduced its holding in IDEXX by 22.4% in Q3, selling 68,510 shares and leaving 236,670 shares valued at about $151.2 million.
• Q results and outlook: IDEXX reported $2.92 EPS (missing estimates by $0.01) and $1.09B revenue (+14.3% YoY) and set FY2026 guidance of $14.29–$14.80 per share; the stock trades with a ~$48.4B market cap and a ~46.6 P/E.
• Insider selling picked up recently — the CEO sold 23,326 shares (~$15.3M) and the EVP sold 1,758 shares (~$1.12M), with insiders offloading 45,957 shares (~$29.9M) over the past three months.

Barclays PLC reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 22.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 236,670 shares of the company's stock after selling 68,510 shares during the quarter. Barclays PLC owned 0.30% of IDEXX Laboratories worth $151,206,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. J.Safra Asset Management Corp acquired a new position in shares of IDEXX Laboratories during the 3rd quarter valued at $31,000. Armstrong Advisory Group Inc. boosted its position in IDEXX Laboratories by 55.9% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company's stock worth $34,000 after purchasing an additional 19 shares during the period. Salomon & Ludwin LLC acquired a new stake in IDEXX Laboratories in the 3rd quarter valued at $35,000. Greykasell Wealth Strategies Inc. acquired a new stake in IDEXX Laboratories in the 3rd quarter valued at $35,000. Finally, WealthCollab LLC purchased a new position in IDEXX Laboratories in the second quarter valued at about $30,000. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Trading Down 1.7%

NASDAQ:IDXX opened at $608.41 on Friday. The stock has a market cap of $48.44 billion, a price-to-earnings ratio of 46.55, a price-to-earnings-growth ratio of 3.70 and a beta of 1.66. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The business's 50-day simple moving average is $666.94 and its 200 day simple moving average is $668.42.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts' consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the business earned $2.53 EPS. IDEXX Laboratories's revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 1,758 shares of the firm's stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the completion of the sale, the executive vice president owned 18,141 shares of the company's stock, valued at approximately $11,511,734.37. This trade represents a 8.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the company's stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the completion of the sale, the chief executive officer directly owned 83,606 shares in the company, valued at $54,975,125.30. This represents a 21.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 45,957 shares of company stock valued at $29,862,109. Corporate insiders own 0.98% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on IDXX. UBS Group reduced their price objective on IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 3rd. Barclays dropped their target price on IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating on the stock in a report on Thursday, February 5th. Piper Sandler reduced their price target on IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating on the stock in a research report on Monday, February 9th. BTIG Research decreased their price target on IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating for the company in a report on Tuesday, February 3rd. Finally, Weiss Ratings downgraded shares of IDEXX Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Thursday, January 29th. Seven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and a consensus price target of $783.33.

About IDEXX Laboratories

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.